DAX24.240 +0,1%Est505.675 +0,1%MSCI World4.343 -0,1%Top 10 Crypto14,88 -2,1%Nas23.205 +1,2%Bitcoin96.161 +0,2%Euro1,1624 ±0,0%Öl65,69 -0,4%Gold4.112 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Beyond Meat A2N7XQ TKMS thyssenkrupp Marine Systems TKMS00 Rheinmetall 703000 NVIDIA 918422 Porsche vz. PAG911 Amazon 906866 Deutsche Telekom 555750 DroneShield A2DMAA Novo Nordisk A3EU6F Lufthansa 823212 SAP 716460 RENK RENK73 Tesla A1CX3T AMD (Advanced Micro Devices) 863186 Siemens Energy ENER6Y
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Handelsstreit im Blick: DAX geht im Plus ins Wochenende -- US-Börsen schließen stärker -- Intel: Starke Zahlen -- HENSOLDT, Lufthansa, DroneShield, SuperMicro, TKMS, Beyond Meat, Dow im Fokus
Top News
Langfristig investieren trotz Kursschwankungen: Diese 10 Regeln helfen in volatilen Zeiten den Überblick zu behalten Langfristig investieren trotz Kursschwankungen: Diese 10 Regeln helfen in volatilen Zeiten den Überblick zu behalten
Die clevere Alternative zum Tagesgeld: Geldmarktnahe-ETFs von Amundi Die clevere Alternative zum Tagesgeld: Geldmarktnahe-ETFs von Amundi
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF - Jetzt informieren!

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
163,86 EUR -1,40 EUR -0,85 %
BMN
190,46 USD +0,05 USD +0,03 %
nachbörslich
BTT
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.394,64 Mrd. EUR

KGV24,98Div. Rendite3,40%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
PR NewswirePublished in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
EN, Johnson & JohnsonPublished in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies
PR NewswireIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
Wer­bungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EN, Johnson & JohnsonIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
EN, Johnson & JohnsonJohnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025
EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy
EN, Johnson & JohnsonSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
PR NewswireSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
PR NewswireTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
EN, Johnson & JohnsonTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
EN, Johnson & JohnsonJohnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types
EN, Johnson & JohnsonJohnson & Johnson announces intent to separate its Orthopaedics business
EN, Johnson & JohnsonJohnson & Johnson reports Q3 2025 results; raises 2025 sales outlook
EN, Johnson & JohnsonJohnson & Johnson Launches INHANCE INTACT™: A Total Shoulder Replacement System Designed for Tissue-Sparing Surgery Providing Day-One Post-Op Mobility
EN, Johnson & JohnsonJohnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care*
PR NewswireJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
EN, Johnson & JohnsonJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
EN, Johnson & JohnsonU.S. FDA approves SIMPONI® (golimumab) for the treatment of pediatric ulcerative colitis
EN, Johnson & JohnsonTREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
EN, Johnson & JohnsonIcotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
PR NewswireIcotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
PR NewswireTREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
PR NewswireJohnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
EN, Johnson & JohnsonJohnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
EN, Johnson & JohnsonU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
PR NewswireU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
EN, Johnson & JohnsonThe Johnson & Johnson Foundation Announces $5 Million Expanded Investment in Africa Frontline First Catalytic Fund to Strengthen the Community Health Workforce
EN, Johnson & JohnsonJohnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR
EN, Johnson & JohnsonTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
PR NewswireTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
EN, Johnson & JohnsonJohnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
EN, Johnson & JohnsonTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
PR NewswireTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
EN, Johnson & JohnsonIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
PR NewswireIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
EN, Johnson & JohnsonJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson Announces Launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter in Europe to Transform Treatment of Difficult-to-Cross Calcified Lesions
PR NewswireJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
EN, Johnson & JohnsonU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
PR NewswireU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.